| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d025f648027e166f146610e4520f221c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c7da9064f16bf42b16a1d6bdfb76d7a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f28817fba3808a82ab9e7d65a33d02b6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-90694 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y107-03003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M5-168
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5308 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate |
2010-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b05671d43eaad94a474eeda6b18e77f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcf6ebae3c10ebc7138184670eb2a8d1 |
| publicationDate |
2010-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2010151823-A1 |
| titleOfInvention |
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy |
| abstract |
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10883087-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10160958-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10195153-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9885024-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9492444-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11639927-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10172797-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10731139-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9926537-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9707184-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9926538-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10639281-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10823727-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4021482-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11098289-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11345899-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10139399-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10792254-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11598767-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9670467-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11781119-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10959958-B2 |
| priorityDate |
2009-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |